Azitra Inc Compliance Plan Approved by NYSE American

An update from Azitra Inc ( (AZTR) ) is now available.

Azitra, Inc. announced that NYSE American has approved its compliance plan to meet the exchange’s minimum stockholders’ equity requirement by April 1, 2027. While the company’s listing remains active during the plan period, failure to meet milestones or regain compliance by the deadline could lead to delisting proceedings, creating potential implications for operations and investor confidence.

The most recent analyst rating on (AZTR) stock is a Hold with a $0.37 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.

Spark’s Take on AZTR Stock

According to Spark, TipRanks’ AI Analyst, AZTR is a Neutral.

Azitra Inc’s overall stock score is primarily impacted by its financial performance, characterized by strong revenue growth but overshadowed by high losses and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is weak due to a negative P/E ratio. The compliance notice from NYSE adds further risk.

To see Spark’s full report on AZTR stock, click here.

More about Azitra Inc

Azitra, Inc. is a clinical-stage biopharmaceutical company specializing in precision dermatology. The company develops innovative therapies including ATR-12, targeting Netherton syndrome, and ATR-04, used in EGFR inhibitor-associated rash treatment. Azitra utilizes a proprietary platform enhanced by artificial intelligence to analyze a microbial strain library for drug development.

Average Trading Volume: 2,583,921

Technical Sentiment Signal: Sell

Current Market Cap: $3.22M

For detailed information about AZTR stock, go to TipRanks’ Stock Analysis page.